InspireMD, Inc. (NSPR)
| Market Cap | 54.91M |
| Revenue (ttm) | 8.98M |
| Net Income (ttm) | -48.79M |
| Shares Out | 48.16M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,076 |
| Open | 1.210 |
| Previous Close | 1.210 |
| Day's Range | 1.120 - 1.230 |
| 52-Week Range | 1.140 - 2.932 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 4.00 (+250.88%) |
| Earnings Date | May 4, 2026 |
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection syste... [Read more]
Financial Performance
In 2025, InspireMD's revenue was $8.98 million, an increase of 28.11% compared to the previous year's $7.01 million. Losses were -$48.79 million, 52.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NSPR stock is "Buy" and the 12-month stock price target is $4.0.
News
InspireMD to Announce First Quarter 2026 Financial Results
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fir...
InspireMD Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel carotid stent with MicroNet mesh is driving a shift from surgery to stenting, supported by strong clinical outcomes, CMS reimbursement changes, and a robust commercial strategy. Financially, the company is well-capitalized through 2027, with plans for further expansion and new product launches.
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upco...
InspireMD Earnings Call Transcript: Q4 2025
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announc...
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fou...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announce...
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE N...
InspireMD Transcript: Piper Sandler 37th Annual Healthcare Conference
CREST-2 trial results and CMS policy changes are accelerating the shift to endovascular stenting for carotid disease, with strong physician support and early commercial traction in the U.S. The company is executing a controlled launch, reporting strong Q3 results and advancing its pipeline with key trials targeting 2026–2027 regulatory milestones.
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis C...
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fir...
InspireMD Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 39% year-over-year to $2.5M, driven by the U.S. launch of CGuard Prime and international demand. Gross margin improved to 34.2%, while net loss widened to $12.7M due to commercial expansion. Q4 revenue is expected at $2.5–$3.0M.
InspireMD Reports Third Quarter 2025 Financial Results
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue
InspireMD Names Peter A. Soukas, M.D.
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...
InspireMD to Announce Third Quarter 2025 Financial Results
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its thir...
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announc...
InspireMD Transcript: H.C. Wainwright 27th Annual Global Investment Conference
At the HC Wainwright conference, a new FDA-approved carotid stent with proprietary mesh technology was introduced, targeting a rapid shift from surgery to stenting in a $1B U.S. market. Strong clinical data, robust patent protection, and significant capital support underpin a focused commercial expansion.
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcom...
InspireMD Earnings Call Transcript: Q2 2025
FDA approval of CGuard Prime enabled a U.S. launch, with early commercial traction and strong physician interest. Q2 revenue grew 2% year-over-year, but net loss widened due to higher operating expenses from U.S. expansion. Over $58 million in new financing supports growth and commercial scale.
InspireMD Reports Second Quarter 2025 Financial Results
--- Management to host investor conference call today, August 5 th , at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid st...
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...
InspireMD Announces Combined Financings of $58 Million
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...
InspireMD to Announce Second Quarter 2025 Financial Results
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release it...
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch...
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. ...